MapLight Drug Discovery Technology Recognized as a Leading Artificial Intelligence Platform
-
MapLight’s drug discovery algorithm has been recognized with first-place rankings by Therapeutics Data Commons (TDC), an evaluator of therapeutic-focused machine learning algorithms
-
To accelerate the development of drugs based on its discovery platform, MapLight has developed machine learning algorithms and integrated them in its internal drug discovery programs
-
MapLight’s discovery platform of optogenetics, transcriptomics, and STARmap has enabled the discovery of multiple drug targets as the foundation of a promising neuroscience pipeline
SAN FRANCISCO, NOVEMBER 14, 2023 – MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, today announced that MapLight’s novel artificial intelligence/machine learning (AI/ML) algorithm has been recognized as an industry-leading platform. MapLight’s internally developed machine learning (ML) algorithm has contributed to the rapid growth of MapLight’s pipeline of potential CNS therapeutics by enabling efficient drug optimization.
The predictive power of MapLight’s platform has been recognized with first-place rankings by Therapeutics Data Commons (TDC), an evaluator of therapeutic-focused artificial intelligence (AI) algorithms. The TDC ranks machine learning algorithms with a focus on drug therapeutics. The TDC evaluated MapLight’s ML algorithm across absorption, distribution, metabolism, excretion, and toxicity (ADMET) property prediction tasks. MapLight submitted two models to the TDC leaderboards. When compared to all other algorithms assessed by the TDC, one of MapLight’s models ranked first in half of the drug property benchmarks. Across both models, MapLight achieved top-5 results on all of the 22 benchmarks TDC evaluates.
“This is a wonderful accomplishment for our team and an important validation of MapLight’s expertise in leveraging artificial intelligence to accelerate discovery efforts.” stated Christopher Kroeger, M.D., MBA, Chief Executive Officer of MapLight. “While some biopharma companies promote artificial intelligence as their sole platform technology for drug discovery, MapLight has taken a different approach. AI/ML is additive to our proprietary target discovery platform and our artificial intelligence tools have helped us to accelerate selection of the best drug candidates for our pipeline targets.”
“We believe that MapLight’s ML algorithm has improved our ability to rapidly identify the drug candidates with the highest potential to be both potent and safe,” added Jim Notwell, Ph.D., who led the MapLight effort. “We can then progress those drug candidates into clinical development more quickly, and ultimately accelerate the timelines for getting these novel therapies to the patients that need them.”
To learn more and access the repository that contains the source code for MapLight’s Therapeutic Data Commons ADMET Benchmark Group submission, visit GitHub and read the preprint arXiv article.
About MapLight Therapeutics
MapLight Therapeutics is working to develop targeted, novel therapeutics to improve the lives of people with difficult-to-treat brain disorders. The company’s unique discovery platform combines novel, proprietary technologies to uncover the individual circuits that misfire in brain disorders and target those circuits with effective, safe therapeutics. MapLight was founded by a team of renowned neuroscientists who led the discovery of such groundbreaking technologies as optogenetics and STARmap. Learn more at www.maplightrx.com.
###
Media Contact for MapLight Therapeutics
Charmaine Lykins, Chief Commercial Officer, clykins@maplightrx.com
